Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
24 janv. 2019 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer
27 nov. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
Asterias Biotherapeutics Reports Third Quarter Results
09 nov. 2018 16h10 HE
|
Asterias Biotherapeutics
Clinical Programs Continue to ProgressRecent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating ExpensesRecently Announced Definitive Merger Agreement with...
Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
02 nov. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study
31 oct. 2018 09h45 HE
|
Asterias Biotherapeutics
Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology...
Asterias Biotherapeutics Announces Facilities and IP License Option Agreements
01 oct. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
20 sept. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
12 sept. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
04 sept. 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference
29 août 2018 07h00 HE
|
Asterias Biotherapeutics
FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...